Clinical trialPhase 1Recruiting
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
Phase 1b Trial of Combined PRMT5 Inhibition With BMS-986504 and PARP Inhibition With Olaparib in Patients With Advanced Cancer With MTAP Loss
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 12 February 2026
- Expected end
- 31 January 2032
- Enrollment
- 36 participants
- Sites
- 1
- Primary outcomes
- Safety and Adverse Events (AEs)
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 12 August 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The goal of this clinical research study is to learn about the safety and effects of BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss.
Detailed description public domain (ClinicalTrials.gov)
Primary Objective: 1\. To determine the safety and tolerability of BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss. Secondary Objectives: 1. To characterize the PK profile of BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss. 2. To determine the preliminary antitumor activity of BMS-986504 in combination with olaparib with advanced solid tumors with MTAP loss. 3. To evaluate the pharmacodynamic activity of BMS-986504 in combination with olaparib in advanced solid tumors with MTAP loss. 4. To evaluate predictors of response and resistance to BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss.